Novo Nordisk's Rare Disease Bet: Can It Offset GLP-1 Losses?
💡 Key Takeaway
Novo Nordisk's rare disease pipeline offers a promising diversification play, but it's unlikely to fully offset the company's mounting GLP-1 market share losses to Eli Lilly and other rivals.
What Happened: Novo's Rare Disease Push
Novo Nordisk recently highlighted progress in its rare disease pipeline, securing regulatory approvals for Frehemgo and Sogroya, and reporting DKK 9.1 billion in rare disease revenue. These developments signal the company's intent to build a new growth pillar beyond its core GLP-1 franchise.
The rare disease portfolio includes treatments for conditions like hemophilia, growth disorders, and sickle cell disease. Novo has been investing in this space for years, but the recent approvals mark a tangible step toward commercialization.
However, the news comes amid a challenging backdrop for Novo. The company has been losing GLP-1 market share to Eli Lilly's Mounjaro and Zepbound, which generated a combined $27.7 billion in first-half 2026 sales. Novo's stock is down 22.5% year-to-date, reflecting investor concerns.
While the rare disease revenue is growing, it remains a small fraction of Novo's total sales, which are still heavily reliant on GLP-1 drugs like Ozempic and Wegovy. The question is whether rare disease can become a meaningful growth driver.
Analysts have a mixed view, with Novo carrying a Zacks Rank #3 (Hold). The rare disease pipeline is a positive, but it's not yet enough to offset the competitive pressures in obesity and diabetes.
Why It Matters: Diversification vs. Competition
For investors, Novo's rare disease push matters because it could reduce the company's dependence on GLP-1 drugs, which are facing intense competition. A diversified revenue base would make Novo more resilient if GLP-1 growth slows.
However, the rare disease market is niche and often requires complex, expensive therapies. It may not deliver the blockbuster returns that GLP-1 drugs have. Novo's rare disease revenue of DKK 9.1 billion is modest compared to its GLP-1 sales, which are in the tens of billions.
Meanwhile, competitors are not standing still. Eli Lilly is expanding its pipeline with oral Foundayo and retatrutide, while Viking Therapeutics and Structure Therapeutics are advancing their own GLP-1 candidates. This intensifies the pressure on Novo to defend its market share.
The stock's underperformance suggests that investors are skeptical about Novo's ability to regain momentum. The rare disease news provides a glimmer of hope, but it's not a game-changer on its own.
Ultimately, Novo's future depends on its ability to innovate across both rare disease and GLP-1. If it can successfully diversify, the stock could be undervalued. But if GLP-1 losses accelerate, the rare disease pipeline may not be enough to compensate.
Source: Zacks Investment Research
Analysis generated by Bobby AI quantitative model, reviewed and edited by our research team. This is not financial advice. Always do your own research before making investment decisions.
Bobby Insight
Hold Novo Nordisk for now; the rare disease pipeline is a long-term positive, but GLP-1 headwinds are too strong to ignore.
Novo's rare disease progress is encouraging, but it won't meaningfully offset GLP-1 market share losses in the near term. The stock's 22.5% YTD decline reflects these challenges, and without a clear catalyst, upside is limited. Investors should wait for signs of stabilization in GLP-1 sales before adding to positions.
What This Means for Me
